Carnitine status in fit and pre-frail/frail elderly compared to healthy young individuals

Completed

• Conditions: veroudering; ageing; increasing age

• Registration Number: NL-OMON43161
• Lead Sponsor: Wageningen Universiteit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 78

Inclusion Criteria

Healthy young subjects (n <= 26):
* 20 * 30 years of age
* BMI of 20 * 25 kg/m2;Healthy fit elderly subjects (n <= 26):
* * 75 years of age
* Fried score <= 0 ;Pre-frail/frail elderly (n<=26):
* * 75 years of age
* Fried score * 1*;Male/female ratio of the different groups will be matched.

Exclusion Criteria

- Contra-indication for DEXA-scan, e.g. metal splinters
- Contra-indication for muscle biopsy, e.g. use of anticoagulants.
- a significant medical or surgical event or hospitalization within the previous three months
- currently or the last three months treated by a medical specialist
- diagnosed with cardiac failure, COPD or anaemia
- diagnosed dementia and not having access to a daily caregiver and not able to make their own trade-off, which will be assessed at our discretion. The potential subjects have to be able to reproduce what is said;
- diagnosed with cancer or receiving cancer treatment
- not able to understand the Dutch language
- Diagnosed neuromuscular disorders
- taking carnitine supplements
- current participation in other research
- usage of the following medications:
o Systemic corticosteroids
o Fibrates
o Valproic acid
o Emetine
o Zidovudine;Additional exclusion criteria for the young individuals:
- Pregnant and nursing women
- Diabetes Mellitus type I and II
- Limited amount of performing sports, not more than 5 times a week

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary study paramater is intramuscular carnitine levels and the<br /><br>intramuscular carnitine derivatives. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>The secondary study parameters are:<br /><br>- carnitine status and its derivates in PBMCs<br /><br>- mitochondrial function in muscle tissue and PBMCs<br /><br>- Fat and fat-free mass<br /><br>- Plasma carnitine and its derivatives<br /><br>- Short Physical Performance Battery<br /><br>- 400m walk time<br /><br>- Cognitive function</p><br>